Digital pathology firm Techcyte has launched Fusion, its first open, standards-based, SaaS platform designed to unify anatomic and clinical pathology workflows.
By bringing together pathology teams, IT systems, and AI into a single, integrated platform, Fusion aims to eliminate workflow silos, enhance diagnostic accuracy, and improve interoperability, setting a new industry standard for digital pathology.
Developed in collaboration with experienced digital pathologists, Techcyte says Fusion represents the next generation of digital pathology, where stakeholders work together on a unified platform, and AI-powered tools are seamlessly embedded into clinical practice to optimise efficiency, collaboration, and patient outcomes.
Pathologists today face multiple disconnected systems, fragmented data sources, and manual workflows, all of which slow down efficiency and decision making. Fusion eliminates these inefficiencies by seamlessly integrating patient data, whole slide imaging, laboratory information systems (LIS), communication tools, and AI-powered diagnostics, enabling pathologists to make faster, more informed diagnoses.
“We have successfully delivered over 5,000,000 clinical AI diagnoses to veterinary, environmental, and clinical pathology,” said Ben Cahoon, CEO of Techcyte. “By adding anatomic pathology to Fusion, we’re shaping what it means to have a complete, unified digital pathology platform. Fusion's strength lies in uniting pathology practice stakeholders within a singular, AI-driven, workflow-first platform to improve efficiency and positively impact patient care.”
Designed as a cloud-native software as a service (SaaS) solution, Fusion is built on industry standards, including DICOM, FHIR, HL7, and DICOMWeb, ensuring seamless integration with the LIS, EHR, slide scanners, and image management systems such as VNAs. Its open architecture enables laboratories to incorporate third-party AI, alongside Techcyte’s proprietary AI, unlocking new diagnostic insights and enhancing workflow efficiency.
“Pathology is going digital, but adoption has been hampered by proprietary systems, limited use of standards, and an insufficient focus on workflow.” said Tiffany Chen, Chief Medical Officer at Techcyte. “Fusion is fully committed to using standards to ensure customers have long-term, durable, portable data and systems.”
Digital pathology offers the potential to revolutionise diagnostic efficiency and accuracy, but achieving these benefits requires seamless AI integration within clinical workflows. Techcyte says its Fusion platform realises this vision by uniting AI, pathologists, and technology into a streamlined system. Through in-house innovation and partnerships with AI vendors, Fusion empowers laboratories with tools that have the potential to enhance efficiency, improve accuracy, and elevate diagnostic confidence. Fusion ensures AI is a core component of the diagnostic process, finally delivering on the long-promised potential of digital pathology.
Techcyte’s anatomic and clinical pathology platform is for Research Use Only in the United States.